Life Science; 2011. 20. Harada A, Matsui Y, Mizuno M, Tokuda H, Niino N, Ohta T. Japanese orthopedists’ interests in prevention of fractures in the elderly from falls. Osteoporos Int. 2004;15(7):560?66. 21. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an elevated fracture danger: critique from the literature. Drugs Aging. 2012;29(3): 191?03. 22. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 2005;28(eight):721?30. 23. Kanis JA, Johnell O, Black DM, et al. Impact of raloxifene around the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis on the A number of Outcomes of Raloxifene Evaluation trial. Bone. 2003;33(three):293?00. 24. Takada J, Miki T, Imanishi Y, et al. Effects of raloxifene therapy around the structural geometry of the proximal femur in Japanese females with osteoporosis. J Bone Miner Metab. 2010;28(5):561?67. 25. Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structural effects of raloxifene on the proximal femur: results in the Various Outcomes of Raloxifene Evaluation Trial. Osteoporos Int. 2006;17(four): 575?86. 26. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010;21(four):655?66. 27. Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the improve on the degree of mineralization of bone in postmenopausal females. J Clin Endocrinol Metab. 2003;88(9):4199?205. 28. Nakamura T, Liu JL, Morii H, et al. Impact of raloxifene on clinical fractures in Asian ladies with postmenopausal osteoporosis. J Bone Miner Metab. 2006;24(five):414?18. 29. Gorai I, Tanaka Y, Hattori S, Iwaoki Y. Assessment of adherence to remedy of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese females. J Bone Miner Metab. 2010;28(two):176?84.156311-83-0 Data Sheet 30.7361-31-1 Purity Ando H, Otoda T, Ookami H, et al. Dosing time-dependent impact of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal females with osteoporosis. Clin Exp Pharmacol Physiol. 2013;40(3):227?32. 31. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly girls with osteoporosis. Yonsei Med J. 29 2008;49(1):119?28. 32. Gorai I, Hattori S, Tanaka Y, Iwaoki Y. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifenealone therapy in postmenopausal Japanese ladies with osteoporosis or osteopenia.PMID:33449821 J Bone Miner Metab. 2012;30(three):349?58. 33. Majima T, Komatsu Y, Shimatsu A, et al. Efficacy of combined therapy with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocr J. 2008;55(1):127?34. 34. Hayashi T, Ina K, Maeda M, Nomura H. The effects of selective estrogen receptor modulator remedy following hormone replacement therapy on elderly postmenopausal women with osteoporosis. Nitric Oxide. 2011;24(4):199?03. 35. Morii H, Ohashi Y, Taketani Y, et al. Impact of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal females with osteoporosis: benefits from a randomized placebo-controlled trial. Osteoporos Int. 20.
